Biosimilar Blocking Strategies: Janssen Gets Day In Court, Amgen Seeks FDA Docs
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and Janssen will face off May 19 ahead of possible June 30 Inflectra launch; in other litigation, Amgen wants Hospira to turn over Epogen biosimilar manufacturing info and regulatory correspondence.